This session brings together senior in-house patent litigators involved in some of the most influential recent pharma and biotech cases, to examine how life sciences litigation strategy is shifting and what in-house teams should be preparing for next.

• Review key cases and court decisions from the past year, and what they reveal about where pharma and biotech patent litigation is evolving.
• How PTAB procedural developments are changing risk assessment, sequencing, and settlement strategy.
• Review venue selection within the US and consider when long-arm litigation can create leverage.

A concise review of recent US trade secret decisions that are shaping how courts assess reasonable measures, access, and remedies. This session brings together judges from key US jurisdictions to discuss the evolving expectations and outcomes from the most influential recent trade secret cases.